Analysts Set Insmed, Inc. (NASDAQ:INSM) Price Target at $205.77

Shares of Insmed, Inc. (NASDAQ:INSM) have received a consensus rating of “Moderate Buy” from the twenty-three research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $204.3333.

Several research analysts have recently weighed in on the stock. Rothschild & Co Redburn assumed coverage on shares of Insmed in a report on Thursday, December 4th. They issued a “buy” rating and a $263.00 price target on the stock. TD Cowen set a $241.00 target price on Insmed in a research note on Thursday, December 18th. HC Wainwright lowered their price objective on shares of Insmed from $240.00 to $230.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Mizuho set a $212.00 target price on shares of Insmed in a research report on Thursday, December 18th. Finally, The Goldman Sachs Group increased their target price on Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research note on Monday, December 15th.

Insider Activity at Insmed

In related news, CEO William Lewis sold 19,215 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00. Following the completion of the sale, the chief executive officer owned 306,891 shares in the company, valued at $51,864,579. The trade was a 5.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Leo Lee sold 75,000 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $195.90, for a total transaction of $14,692,500.00. Following the transaction, the director owned 54,677 shares in the company, valued at $10,711,224.30. The trade was a 57.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 286,100 shares of company stock worth $52,595,894 in the last quarter. 3.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Insmed

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Insmed by 13.0% during the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after buying an additional 2,291,328 shares during the period. Norges Bank bought a new stake in shares of Insmed in the 2nd quarter valued at about $194,728,000. Artisan Partners Limited Partnership boosted its holdings in Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after acquiring an additional 1,623,342 shares during the period. Orbis Allan Gray Ltd bought a new position in Insmed during the 2nd quarter worth approximately $153,389,000. Finally, Darwin Global Management Ltd. grew its position in Insmed by 5.8% during the 3rd quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock worth $2,897,797,000 after acquiring an additional 1,112,824 shares during the last quarter.

Insmed Stock Down 4.4%

INSM stock opened at $156.32 on Friday. The stock has a 50-day simple moving average of $185.75 and a two-hundred day simple moving average of $155.66. Insmed has a twelve month low of $60.40 and a twelve month high of $212.75. The firm has a market capitalization of $33.34 billion, a PE ratio of -25.25 and a beta of 1.08. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The firm had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. Insmed’s revenue was up 52.4% compared to the same quarter last year. During the same quarter last year, the business posted ($1.27) earnings per share. On average, equities analysts predict that Insmed will post -4.56 EPS for the current fiscal year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.